Skip to main content

RNeasy Mini Kit

High-quality total RNA in minutes.

Investigator 24plex QS Kit

Multiplex amplification for human ID, with CODIS and European standard markers.

QIAsphere

Monitor and manage your QIAsphere-ready instruments from anywhere, using any mobile device.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Find out more

QIAGENbioinformatics.com

COVID-19 testing and research

Up to date protocols and list of COVID-19 testing and research solutions.

RNeasy Mini Kit

High-quality total RNA in minutes.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QuantiFERON-TB Gold Plus

Detect TB infection with confidence.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Directors Dealings

Home  >  Investor Relations  >  Financial Reports & SEC Filings  >  Directors Dealings

QIAGEN publishes information on directors' dealings as reported to the company and pursuant to regulations by the United States Securities and Exchange Commission (SEC) and the Netherlands Authority for the Financial Markets (A-FM) pursuant to Section 2a Wmz 1996 and Art. 19. EU Directive No. 596/2014. Our insider trading policy can be downloaded as PDF document here.

Notes to the overview of recent transactions

* Cashless Exercise

1) According to a Rule 10b5-1 long-term Sales Plan ("Langzeitverkaufsvertrag").

2) Lawrence A. Rosen, Metin Colpan, Toralf Haag, Ross L. Levine, Elaine R. Mardis, Bert van Meurs, Eva van Pelt, Eva Pisa, Elizabeth E. Tallett, Stephen H. Rusckowski.

“Net share settlement” is done when a number of shares to cover expenses related to the grant release (such as taxes and transaction costs) are withheld by the Company.

Recent Transactions

Name and function Date and type Financial instrument Amount of shares SEC BAFin A-FM

Lawrence A. Rosen,

Supervisory Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

4,338

 

PDF PDF

Metin Colpan,

Supervisory Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

4,243

 

PDF PDF

Toralf Haag,

Supervisory Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

1,815

 

PDF PDF

Ross L. Levine,

Supervisory Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

3,803

 

PDF PDF

Elaine R. Mardis,

Supervisory Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

3,998

 

PDF PDF

Elizabeth E. Tallett

Supervisory Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

4,487

 

PDF PDF

Thierry Bernard,

Managing Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

106,903

 

PDF PDF

Roland Sackers,

Managing Director

02/28/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

79,753

 

PDF PDF

All Supervisory Board Directors 2)

 

02/28/25 Grant

Restricted Stock Units

 

5,990

 

PDF PDF

Thierry Bernard,

Managing Director

02/28/25 Grant

Performance Stock Units

 

143,229

 

PDF PDF

Roland Sackers,

Managing Director

02/28/25 Grant

Performance Stock Units

 

80,098

 

PDF PDF

Thierry Bernard,

Managing Director

02/27/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

434

 

PDF PDF

Roland Sackers,

Managing Director

02/27/25

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

4,736

 

PDF PDF

Lawrence A. Rosen,

Supervisory Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

415

 

PDF PDF

Metin Colpan,

Supervisory Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

4,910

 

PDF PDF

Toralf Haag,

Supervisory Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

73

 

PDF PDF

Ross L. Levine,

Supervisory Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

465

 

PDF PDF

Elaine Mardis,

Supervisory Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

114

 

PDF PDF

Elizabeth E.Tallett,

Supervisory Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

1,351

 

PDF PDF

Stephen H. Rusckowski,

Supervisory Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

1

 

PDF PDF

Thierry Bernard,

Managing Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

8,919

 

PDF PDF

Roland Sackers,

Managing Director

01/28/25

Common Shares

(Following the terms of the synthetic share repurchase by QIAGEN N.V., every 36 issued QIAGEN shares were consolidated into 35 QIAGEN shares.)

10,951

 

PDF PDF